All In Biotech

Drug Trial Radar · NCT03937479

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Ranging Study to Assess the Effect of RPL554 Added on to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

416

Actual

Start

May 1, 2019

Primary completion

Nov 15, 2019

Study completion Nov 15, 2019

Sponsor

Sponsor type
Industry
Collaborators
IQVIA Pty Ltd; LGC Limited
First posted
May 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.

Conditions

  • COPD

Interventions

  • Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropiumDrug

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropiumDrug

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropiumDrug

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropiumDrug

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

  • Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropiumDrug

    Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4Time frame: Baseline and Week 4

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • California Research Medical Group, Inc

    Fullerton, California

  • Southern California Institute For Respiratory Diseases, Inc.

    Los Angeles, California

  • Innovative Clinical Research

    Lafayette, Colorado

  • Meris Clinical Research

    Brandon, Florida

  • Clinical Research of West Florida

    Clearwater, Florida

  • Pulmonary Disease Specialists, PA d/b/a PDS Research

    Kissimmee, Florida

  • Medical Research of Central Florida, LLC

    Leesburg, Florida

  • Clinical Trials of Florida, LLC

    Miami, Florida

  • Peninsula Research, Ormond Beach, LLC

    Ormond Beach, Florida

  • Medsol Clinical Research Center, Inc

    Port Charlotte, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Pasadena Center for Medical Research, LLC

    St. Petersburg, Florida

  • Florida Pulmonary Research Institute, LLC

    Winter Park, Florida

  • Columbus Regional Research Institute

    Columbus, Georgia

  • VitaLink Research - Hamilton Mill

    Dacula, Georgia

  • VitaLink Research - Duluth

    Duluth, Georgia

  • Gwinnett Biomedical Research

    Lawrenceville, Georgia

  • IACT Health

    Rincon, Georgia

  • Vitalink

    Winder, Georgia

  • Genesis Clinical Research and Consulting, LLC

    Fall River, Massachusetts

  • Pulmonary Research Institute of Southeast Michigan

    Farmington Hills, Michigan

  • Cities Research Center

    Fridley, Minnesota

  • American Health Research

    Charlotte, North Carolina

  • Clinical Research of Gastonia

    Gastonia, North Carolina

  • Research Carolina of Huntersville

    Huntersville, North Carolina

  • Clinical Research of Lake Norman

    Mooresville, North Carolina

  • New Horizons Clinical Research

    Cincinnati, Ohio

  • Aventiv Research, Inc

    Columbus, Ohio

  • Aventiv Research, Inc

    Dublin, Ohio

  • Crisor, LLC

    Medford, Oregon

  • Vitalink Research - Anderson

    Anderson, South Carolina

  • Lowcountry Lung and Critical Care, PA

    Charleston, South Carolina

  • VitaLink-Columbia

    Columbia, South Carolina

  • VitaLink Research - Easley

    Easley, South Carolina

  • Piedmont Research Partners, LLC

    Fort Mill, South Carolina

  • VitaLink Research-Gaffney

    Gaffney, South Carolina

  • VitaLink Research-Greenville

    Greenville, South Carolina

  • VitaLink Research-UPSTATE

    Greenville, South Carolina

  • Clinical Research of Charleston

    Mt. Pleasant, South Carolina

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.